Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Prior Auth Duration Update | OpenPaye…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG269

    Authorization Duration Exception-REG

    Customize your policy alerts

    Sign up for Oscar Health Policy PG269 alerts

    Get alerted when Policy PG269 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs minimum or requested authorization durations for prescription drugs subject to prior authorization in Illinois, New Jersey, Oklahoma, and Texas, including state-specific requirements and exceptions.

    Policy Summary
    PayerOscar Health
    PolicyAuthorization Duration Exception-REG
    Policy CodePolicy PG269
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionIdentify the member’s applicable state or residency, prescription drug, treated condition, and requested treatment duration in the prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4States with specific authorization duration rules
    6 monthsMinimum qualifying authorization duration
    12 monthsQualifying Illinois chronic or Texas condition duration
    36 monthsQualifying Oklahoma chronic-condition duration
    180 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    New Jersey authorization validity

    State-Specific Authorization Duration Criteria

    Illinois Acute or Non-Chronic Conditions

    The Plan will provide at least 6 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:

    ALL of the following

    • The member's plan is issued for Illinois.
    • The prescription drug is being prescribed to treat a non-chronic condition.
    • The prescription drug is NOT a benzodiazepine or Schedule II narcotic drug.

    Illinois Chronic Conditions

    The Plan will provide at least 12 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:

    ALL of the following

    • The member's plan is issued for Illinois.
    • The prescription drug is being prescribed to treat a chronic or long-term condition.
    • The prescription drug is NOT a benzodiazepine or Schedule II narcotic drug.

    New Jersey Chronic Conditions

    The Plan will provide at least 6 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:

    ALL of the following

    • The member's plan is issued for New Jersey.
    • The prescription drug is being prescribed to treat a chronic or long-term condition.

    Oklahoma Chronic Conditions

    The Plan will provide at least 36 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:

    ALL of the following

    • The member's plan is issued for Oklahoma.
    • The prescription drug is being prescribed to treat a chronic or long-term condition.
    • The prescription drug is on the formulary.
    • The member remains on the same health plan.
    • ALL of the following

      • There are NO clinical criteria changes to the requested drug's prior authorization.

    Texas Autoimmune Disease, Hemophilia, or Von Willebrand Disease

    The Plan will provide at least 12 months of authorization duration for the requested prescription drug when ALL of the following criteria are met:

    ALL of the following

    • The member is a resident of Texas.
    • ONE of the following conditions

      • Autoimmune disease.
      • Hemophilia.
      • Von Willebrand disease.
    • ALL of the following drug criteria

    Illinois Appendix Authorization-Duration Rule

    If the member's plan is issued for Illinois, authorization remains valid for the length of treatment as determined by the member's health care professional, subject to the applicable Illinois duration rule.

    ALL of the following

    • The member's plan is issued for Illinois.
    • The authorization duration is the length of treatment determined by the member's health care professional, subject to the applicable Illinois authorization-duration requirements.

    New Jersey Appendix Authorization-Duration Rule

    Except where shorter time frames are necessary to monitor patient safety or treatment effectiveness, and with notice to the treating provider, a prior authorization for a health care service treating a chronic or long-term care condition remains valid for 180 days. The payer may not require the covered person to obtain another prior authorization for that health care service within the 180-day period.

    ALL of the following

    • The prior authorization is for a health care service treating a chronic or long-term care condition.
    • The 180-day validity period is not shortened because a shorter period is necessary to monitor patient safety or treatment effectiveness, or, if shortened, the treating provider is notified.

    Oklahoma Appendix Authorization-Duration Rule

    If a prior authorization is required for a prescription drug used to treat a chronic condition and the enrollee remains on the same health plan, the authorization remains valid for 3 years from the date the health care provider receives the approval, subject to the applicable exclusions and exceptions.

    ALL of the following

    • The prescription drug is used to treat a chronic condition.
    • The enrollee remains on the same health plan.
    • The authorization has not been affected by a clinical-criteria change, removal of the generic prescription drug from the formulary, or movement of the prescription drug to a less preferred formulary tier.
    • The prescription drug is not an opioid, a controlled substance prohibited from being dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Section 301 et seq., as amended, or a drug for the treatment of weight loss.

    Texas Appendix Annual Prior Authorization Limitation

    A health benefit plan issuer providing prescription drug benefits may not require an enrollee to receive more than one prior authorization annually for a prescription drug prescribed to treat an autoimmune disease, hemophilia, or Von Willebrand disease, subject to the exclusions below.

    ALL of the following

    • The prescription drug treats ONE of the following

      • Autoimmune disease.
      • Hemophilia.
      • Von Willebrand disease.
    • The annual prior authorization limitation is not excluded by the applicable Texas statutory exceptions.

    For Illinois non-chronic conditions, the 6-month authorization duration does not apply to benzodiazepines or Schedule II narcotic drugs. An acute-condition exception applies when the drug's prescribing information specifies a duration that aligns with the duration in the applicable class-, drug-, or indication-specific clinical guideline; in that case, the clinical-guideline duration is used.

    For Illinois chronic conditions, the 12-month authorization duration does not apply to benzodiazepines or Schedule II narcotic drugs. An exception applies when the drug's prescribing information specifies that it is administered as a one-time treatment or has another specified duration; in that case, the duration in the applicable class-, drug-, or indication-specific clinical guideline is used if aligned with the prescribing information.

    For Oklahoma's 36-month authorization duration, exclusions and limitations apply to non-formulary drugs, changes to the member's health plan, clinical-criteria changes, removal of a generic prescription drug from the formulary, movement of a prescription drug to a less preferred formulary tier, opioids, controlled substances prohibited from being dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, and drugs used for the treatment of weight loss. A chronic-condition exception applies when the drug's prescribing information specifies a one-time treatment or other specified duration; the applicable class-, drug-, or indication-specific clinical-guideline duration is then used if aligned with the prescribing information.

    For Texas's 12-month authorization duration, exclusions apply to opioids, benzodiazepines, barbiturates, carisoprodol, prescription drugs with a typical treatment period of less than 12 months, drugs with an FDA boxed warning for the use that require specific provider assessment, and use of a drug other than its FDA-approved use. The applicable class-, drug-, or indication-specific clinical-guideline duration is used when it is longer.

    The Illinois exception does not apply to the prescription of benzodiazepines or Schedule II narcotic drugs, such as opioids.

    The Oklahoma three-year authorization validity rule does not apply to prescription drugs that are opioids, controlled substances prohibited from being dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, or prescription drugs used for the treatment of weight loss. It also does not continue when clinical criteria change, the generic prescription drug is removed from the formulary, or the prescription drug is moved to a less preferred formulary tier.

    The Texas annual prior authorization limitation does not apply to opioids, benzodiazepines, barbiturates, carisoprodol, prescription drugs with a typical treatment period of less than 12 months, drugs with an FDA boxed warning for the use that require specific provider assessment, or use of an FDA-approved drug in a manner other than its approved use.

    Authorization Duration and Submission Requirements

    Prior Authorization

    Illinois Requested Treatment Duration

    For an Illinois-issued plan, provide authorization for the treatment length requested by the member’s health care professional, for initial review or continued care, up to 12 months. If the request does not specify a treatment duration, apply the applicable chronic- or non-chronic-condition criteria.

    • Confirm the requested treatment duration is documented in the prior authorization request.
    • Do not authorize beyond 12 months under this rule.
    Prior Authorization

    Illinois Non-Chronic Condition Duration

    For an Illinois-issued plan, provide at least 6 months of initial or continued-care authorization for a prescription drug treating a non-chronic condition when the drug is not a benzodiazepine or Schedule II narcotic. Authorize 6 months or the longer duration required by the applicable class-, drug-, or indication-specific clinical guideline.

    • Apply the clinical-guideline duration when the drug’s prescribing information specifies a duration aligned with that guideline.
    • The minimum-duration rule does not apply to benzodiazepines or Schedule II narcotics.

    Policy Context

    This guideline addresses the administrative duration of prior authorizations for chronic, long-term, or otherwise qualifying prescription drug treatment. It establishes when state-specific rules extend authorization validity or limit repeat authorization requirements; it does not determine clinical treatment selection. Exceptions remain applicable for safety monitoring, formulary or clinical-criteria changes, controlled substances, short treatment courses, certain boxed-warning drugs, and non-approved uses.

    Policy Definitions

    Acute condition
    DefinitionA condition that is sudden in onset and self-limiting in nature.
    Typical courseGenerally resolves in days or weeks.
    Potential progressionMay lead to a chronic condition if untreated.
    Chronic condition
    DefinitionA condition that develops over a long period.
    Typical courseGenerally persistent or recurring.
    DurationMeasured in months or years.

    Initial Authorization

    Initial Authorization

    State-specific authorization-duration rules apply to the initial review when the following criterion is met.

    Initial authorization duration: The requested prescription drug meets the applicable state-specific criteria for the member's plan or residency.State-specific duration

    The applicable class-, drug-, or indication-specific clinical guideline may provide a longer duration.

    Continued Care Authorization

    Initial Review or Continued Care

    State-specific authorization-duration rules apply to initial review or continued care when the following criterion is met.

    Continued-care duration: The requested prescription drug meets the applicable state-specific criteria for Illinois, New Jersey, Oklahoma, or Texas.State-specific duration

    The applicable class-, drug-, or indication-specific clinical guideline may provide a longer duration.

    Oklahoma Three-Year Continuation

    Continued authorization under Oklahoma chronic-condition rules remains valid when ALL criteria are met.

    Continued Oklahoma validity: The enrollee remains on the same health plan and the prescription drug continues to treat a chronic condition.Authorization remains valid for 3 years
    Policy Summary
    PayerOscar Health
    PolicyAuthorization Duration Exception-REG
    Policy CodePolicy PG269
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionIdentify the member’s applicable state or residency, prescription drug, treated condition, and requested treatment duration in the prior authorization request.
    SourceLink
    On This Page
    State-Specific Authorization Duration CriteriaAuthorization Duration and Submission RequirementsPolicy ContextPolicy DefinitionsInitial AuthorizationContinued Care Authorization
  1. The plan did NOT remove the requested generic prescription drug from the formulary OR the plan did NOT move the requested prescription drug to a less preferred tier status on its formulary.
  2. The prescription drug is NOT an opioid.
  3. The prescription drug is NOT a controlled substance that is prohibited from being dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. Section 301 et seq., as amended.
  4. The prescription drug is NOT for the treatment of weight loss.
  5. The prescription drug is not an opioid, benzodiazepine, barbiturate, or carisoprodol.
  6. The prescription drug does not have a typical treatment period of less than 12 months.
  7. The prescription drug does not have a boxed warning assigned by the United States Food and Drug Administration for use and require specific provider assessment.
  8. The prescription drug is not used in a manner other than the approved use by the United States Food and Drug Administration.
  9. Prior Authorization

    Illinois Chronic Condition Duration

    For an Illinois-issued plan, provide at least 12 months of initial or continued-care authorization for a prescription drug treating a chronic or long-term condition when the drug is not a benzodiazepine or Schedule II narcotic. Authorize 12 months or the longer duration required by the applicable class-, drug-, or indication-specific clinical guideline.

    • Use the applicable clinical-guideline duration when the drug’s prescribing information specifies a one-time treatment or other duration aligned with that guideline.
    • The minimum-duration rule does not apply to benzodiazepines or Schedule II narcotics.
    Prior Authorization

    New Jersey Chronic Condition Duration

    For a New Jersey-issued plan, provide at least 6 months of initial or continued-care authorization for a prescription drug treating a chronic or long-term condition. Authorize 6 months or the longer duration required by the applicable class-, drug-, or indication-specific clinical guideline.

    • Use the applicable clinical-guideline duration when the drug’s prescribing information specifies a one-time treatment or other duration aligned with that guideline.

    Unsupported block type: prior_auth

    Prior Authorization

    Texas Qualifying-Condition Duration

    For a Texas resident, provide at least 12 months of initial or continued-care authorization when the prescription drug treats autoimmune disease, hemophilia, or Von Willebrand disease and satisfies the applicable exclusions. Authorize 12 months or the longer duration required by the applicable class-, drug-, or indication-specific clinical guideline.

    • The drug must not be an opioid, benzodiazepine, barbiturate, or carisoprodol.
    • The drug must not have a typical treatment period of less than 12 months, a boxed warning requiring specific provider assessment, or an unapproved use.
    Documentation Required

    Illinois Authorization Duration

    For Illinois, authorization duration is tied to the date the health care provider receives prior authorization approval or to the treatment length determined by the patient’s health care professional, as applicable.

    • Document the provider’s receipt of prior authorization approval and the treatment duration used for the authorization.
    • This duration exception does not apply to benzodiazepines or Schedule II narcotic drugs, including opioids.
    Prior Authorization

    New Jersey 180-Day Authorization

    For chronic or long-term care conditions in New Jersey, a required prior authorization remains valid for 180 days, and the member generally may not be required to obtain another authorization for the same health care service during that period.

    • A shorter period may be used when necessary to monitor patient safety or treatment effectiveness, with notice to the treating provider.
    Prior Authorization

    Oklahoma Three-Year Authorization

    For an Oklahoma chronic-condition prescription drug, prior authorization remains valid for 3 years from the date the health care provider receives prior authorization approval when the enrollee remains on the same health plan.

    • Confirm the approval-receipt date and continued enrollment in the same health plan.
    • Three-year validity is subject to the clinical-criteria, formulary, plan, and drug-related exceptions below.
    Prior Authorization

    Texas Annual Authorization Limit

    For a Texas qualifying drug prescribed for autoimmune disease, hemophilia, or Von Willebrand disease, do not require more than one prior authorization annually for the prescription drug benefit.

    • Confirm the member is a Texas resident and the prescription drug treats one of the qualifying conditions.
    • The annual limitation does not apply to the excluded drugs, uses, and treatment periods identified below.
    Documentation Required

    State-Specific Duration Documentation

    Document the facts supporting the applicable state-specific authorization duration before submitting or renewing the request.

    • Identify the applicable state or member residency and whether the plan is issued in that state.
    • Identify the prescription drug, treated condition, chronic or non-chronic status, requested treatment duration, and applicable clinical-guideline duration.
    • For continuing authorization, document prior authorization approval, the date the provider received approval, plan enrollment status, formulary status, and any relevant clinical or prescribing-information exceptions.
    Documentation Required

    Shorter Authorization Period Notice

    New Jersey may use an authorization period shorter than 180 days when necessary to monitor patient safety or treatment effectiveness.

    • Provide notice to the treating provider when a shorter authorization period is used.
    Denial Risk

    Oklahoma Authorization Exceptions

    Oklahoma’s three-year prior authorization validity is subject to changes affecting clinical criteria, formulary placement, plan enrollment, and specified drug or use exclusions.

    • The exception applies if clinical criteria change, the plan removes the requested generic prescription drug from the formulary, or moves the requested prescription drug to a less-preferred formulary tier.
    • The member must remain on the same health plan.
    Denial Risk

    Illinois Non-Chronic Drug Exclusion

    Illinois’ six-month minimum authorization for non-chronic conditions does not apply when the requested prescription drug is a benzodiazepine or Schedule II narcotic drug.

    • Do not apply the Illinois non-chronic minimum-duration rule to these controlled substances.
    Denial Risk

    Illinois Chronic Drug Exclusion

    Illinois’ twelve-month minimum authorization for chronic or long-term conditions does not apply when the requested prescription drug is a benzodiazepine or Schedule II narcotic drug.

    • Do not apply the Illinois chronic-condition minimum-duration rule to these controlled substances.
    Denial Risk

    Oklahoma Duration Exclusions

    Oklahoma’s 36-month authorization duration is unavailable when the prescription drug is non-formulary, the member does not remain on the same health plan, or applicable clinical or formulary conditions change.

    • Exclude drugs affected by a clinical-criteria change, removal of the requested generic from the formulary, or movement of the requested drug to a less-preferred tier.
    • The 36-month duration is also unavailable for opioids, prohibited controlled substances, and drugs used for weight loss.
    Denial Risk

    Texas Duration Exclusions

    Texas’ 12-month authorization duration is unavailable for excluded drugs, short treatment periods, specified boxed-warning drugs, and unapproved uses.

    • Exclude opioids, benzodiazepines, barbiturates, and carisoprodol.
    • Exclude prescription drugs with a typical treatment period of less than 12 months.
    • Exclude drugs with an FDA boxed warning for the use requiring specific provider assessment.
    • Exclude use of an FDA-approved drug in a manner other than its approved use.
    Denial Risk

    Oklahoma Excluded Drugs

    Oklahoma’s three-year authorization does not apply to opioids, prohibited controlled substances, or prescription drugs used to treat weight loss.

    • A prohibited controlled substance is one that may not be dispensed without a prescription under the Federal Food, Drug, and Cosmetic Act, as amended.
    Denial Risk

    Texas Excluded Drugs and Uses

    Texas’ annual prior authorization limitation does not apply to specified drugs, treatment periods, boxed-warning uses, or unapproved uses.

    • Excluded drugs: opioids, benzodiazepines, barbiturates, and carisoprodol.
    • Excluded situations: a typical treatment period of less than 12 months; an FDA boxed warning requiring specific provider assessment; or use other than the FDA-approved use.
    Denial Risk

    Illinois Controlled-Substance Exclusion

    The Illinois authorization-duration exception does not apply to prescriptions for benzodiazepines or Schedule II narcotic drugs, including opioids.

    • Apply the ordinary applicable authorization rules rather than the Illinois duration exception for these drugs.
    Autoimmune disease
    DefinitionA condition in which the body's immune system mistakenly attacks and destroys healthy body tissue.
    ExamplesExamples include Crohn's disease, multiple sclerosis, myasthenia gravis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and ulcerative colitis.
    Relevant useA qualifying condition for the Texas authorization-duration rule.
    Hemophilia
    DefinitionA bleeding disorder in which the blood does not clot properly.
    TypesIncludes hemophilia A, hemophilia B, and hemophilia C.
    Bleeding riskMay cause spontaneous bleeding or bleeding after an injury or surgery.
    Von Willebrand disease
    DefinitionA bleeding disorder caused by low levels of von Willebrand factor in the blood or by von Willebrand factor that does not work properly.
    Clotting functionImpaired von Willebrand factor causes blood not to clot properly.
    Relevant useA qualifying condition for the Texas authorization-duration rule.
    Boxed warning
    DefinitionThe highest safety-related warning that the FDA assigns to a drug.
    PurposeBrings attention to major risks of the drug.
    Label locationAppears on the FDA label.
    Authorization
    DefinitionA determination required under a health benefits plan that, based on the information provided, satisfies the plan's medical-necessity requirements.
    IncludesIncludes prior authorization.
    Plan contextMade under the member's health benefits plan.
    Prior authorization
    DefinitionThe process by which a payer determines the medical necessity of an otherwise covered service before the service is provided.
    Review activitiesMay include preadmission review, pretreatment review, utilization review, and case management.
    NotificationMay require the covered person or health care provider to notify the payer before providing a health care service.
    Generally accepted standards of medical practice
    Evidence baseStandards based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community.
    Professional recommendationsInclude recommendations from relevant physician and specialty societies.
    Clinical judgmentInclude the views of physicians practicing in relevant clinical areas.
    Chronic condition
    DefinitionA condition that lasts one year or more.
    Ongoing careRequires ongoing medical attention.
    Daily activitiesMay limit activities of daily living, or both require ongoing attention and limit those activities.

    Clinical-criteria or formulary changes may interrupt the duration. The Oklahoma rule also excludes opioids, certain controlled substances, and prescription drugs used for weight loss.